HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy.

Abstract
Noscapine (Nos), an orally available plant-derived antitussive alkaloid, is in phase II clinical trials for cancer chemotherapy. It has extensively been shown to inhibit tumor growth in nude mice bearing human xenografts of hematopoietic, breast, lung, ovarian, brain, and prostate origin. However, high tumor-suppressive Nos dosages encumber the development of oral controlled-release formulations because of a short biological half-life (<2 h), poor absorption, low aqueous solubility, and extensive first-pass metabolism. Here, we present the design, fabrication, optimization, characterization, and biological evaluation of estrone-conjugated noscapine-loaded gelatin nanoparticles (Nos-ES-GN) for targeting estrogen-receptor-positive breast cancer MCF-7 cells. Gelatin nanoparticles (GN) were a uniformly compact size, stable at physiological pH, and showed a drug entrapment efficiency of 66.1±5.9 and 65.2±5.6% for Nos-GN and Nos-ES-GN, respectively. The secondary structure of gelatin nanocoacervates was predicted using circular dichroism and in-silico molecular modeling. Our data suggest that ethanol-fabricated GN retained the α-helical content of gelatin, whereas acetone favored the formation of random coils. The conjugation of estrone to Nos-GN did not affect the release rate of the drug, and both formulations followed first-order release kinetics with an initial burst, followed by a slow release. The IC50 value of Nos-ES-GN was 21.2 μmol/l, which was ∼50% lower than the free drug (43.3 μmol/l), suggesting targeted drug delivery. Our cell uptake study carried out in an estrogen-receptor-positive (MCF-7) and negative (MDA-MB-231) cancer cell lines showed greater accumulation of Nos-ES-GN in MCF-7 cells instead of MDA-MB-231 cells. Our data indicated that estrone-conjugated nanoparticles may potentially be used for targeting breast cancer cells.
AuthorsJitender Madan, Sushma R Gundala, Yoganjaneyulu Kasetti, Prasad V Bharatam, Ritu Aneja, Anju Katyal, Upendra K Jain
JournalAnti-cancer drugs (Anticancer Drugs) Vol. 25 Issue 6 Pg. 704-16 (Jul 2014) ISSN: 1473-5741 [Electronic] England
PMID24642711 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Antitussive Agents
  • Drug Carriers
  • Receptors, Estrogen
  • Estrone
  • Noscapine
  • Gelatin
Topics
  • Antineoplastic Agents (administration & dosage, chemistry)
  • Antitussive Agents (administration & dosage, chemistry)
  • Breast Neoplasms (drug therapy)
  • Cell Line, Tumor
  • Drug Carriers
  • Drug Delivery Systems
  • Estrone (chemistry)
  • Female
  • Gelatin
  • Humans
  • Inhibitory Concentration 50
  • Molecular Targeted Therapy
  • Nanoparticles
  • Noscapine (administration & dosage, chemistry)
  • Protein Structure, Secondary
  • Receptors, Estrogen (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: